Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Pesnel, Sabrina ^a,b   Pillon, Arnaud ^a   Créancier, Laurent ^a   Lerondel, Stéphanie ^b   Pape, Alain ^b,c   Recher, Christian ^d   Demur, Cécile ^d   Guilbaud, Nicolas ^a   Kruczynski, Anna ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b CNRS   (France)

^c INSERM   (France)

^d CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEXA FLUOR 750 DYE; DYE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HCD44; MONOCLONAL ANTIBODY HCD45; TUMOR MARKER; UNCLASSIFIED DRUG; CD45 ANTIGEN; FLUORESCENT DYE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE IMAGING; CANCER DIAGNOSIS; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE REFLECTANCE IMAGING; HUMAN; HUMAN CELL; IMAGING; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR GROWTH; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; FLOW CYTOMETRY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LONGEVITY; LUMINESCENCE; METABOLISM; METHODOLOGY; MOUSE MUTANT; NEAR INFRARED SPECTROSCOPY; PATHOLOGY; REPRODUCIBILITY; THREE DIMENSIONAL IMAGING; TUMOR CELL LINE;

ALEXA; ANIMALIA; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; IMAGING, THREE-DIMENSIONAL; INJECTIONS, INTRAVENOUS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; LONGEVITY; LUMINESCENT MEASUREMENTS; MICE; MICE, SCID; REPRODUCIBILITY OF RESULTS; SPECTROSCOPY, NEAR-INFRARED;

EID: 84856388493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030690     Document Type: Article

References (24)

1. Isaza MP, Chau JT, Le A, Balashova NV, Patel JK, et al. (2008) A bioluminescent HL-60 cell line to assay anti-leukemia therapeutics under physiological conditions. Luminescence 23 (1): 17-21.
2. McCormack E, Micklem DR, Pindard LE, Siden E, Gallant P, et al. (2007) In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time domain autofluorescence decoupling, fluorohore quantification, and localization. Mol Imaging 6 (3): 193-204.
3. Ghoroghchian PP, Therien MJ, Hammer DA, (2009) In vivo fluorescence: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1 (2): 156-167.
4. Leblond F, Davis SC, Valdés PA, Pogue BW, (2010) Pre-clinical whole body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol 98 (1): 77-94.
5. Krause DS, Spitzer TR, Stowell CP, (2010) The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma. Arch Pathol Lab Med 134 (7): 1033-1038.
6. Goodison S, Urquidi V, Tarin D, (1999) CD44 cell adhesion molecules. J Clin Pathol 52: 189-196.
7. Omary MB, Trowbridge IS, Battifora HA, (1980) Human homologue of murine T200 glycoprotein. J Exp Med 152: 842-852.
8. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ, (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49: 4906-4912.
9. Morris JC, Waldmann TA, (2009) Antibody-based therapy of leukemia. Expert Rev Mol Med 30: 11-29.
10. Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, et al. (2009) Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 114 (6): 1226-1235.
11. Kotzerke J, Bunjes D, Scheinberg DA, (2005) Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant 36 (12): 1021-1026.
12. Créancier L, Menon Y, Pillon A, Verdier J, Chansard N, et al. (2010) Monitoring of tumor progression in orthotopic AML mouse models using quantitative RT-PCR and/or bioluminescence imaging: Application to the targeted cytotoxic agent F14512. Proc Am Assoc Cancer Res Abst 406:101st Washington Annual Meeting.
13. Kalchenko V, Shivtiel S, Malina V, Lapid K, Haramati S, et al. (2006) Use of lipophilic near-infrared dye in whole-body optical imaging of hematopietic cell homing. J Biomed Opt 11 (5): 1-3.
14. Leners N, Ferrant A, Jamar F, (1991) Evaluation of two 111In-oxinate formulations for labelling of white blood cells. Int J Rad Appl Instrum B 18: 727-733.
15. Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, et al. (2002) Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. PNAS 99 (5): 3030-3035.
16. Kuenzle K, Taverna C, Steinert HC, (2002) Detection of extramedullary infiltrates in acute myelogenous leukemia with whole-body positron emission tomography and 2-deoxy-2-[18F]-fluoro-D-glucose. Mol Imaging Biol 4 (2): 179-183.
17. Tomimaru Y, Takeda Y, Tatsumi M, Kim T, Kobayashi S, et al. (2010) Utility of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep 24 (3): 613-620.
18. Olafsen T, Wu AM, (2010) Antibody vectors for imaging. Semin Nucl Med 40 (3): 167-181.
19. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, et al. (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyannatobenzyl-desferrioxamine. Nat Protoc 5 (4): 739-743.
20. Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, et al. (2004) Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging 3 (2): 117-124.
21. Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, et al. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113 (16): 3765-3772.
22. Liu J, Jiang G, (2006) CD44 and hematologic malignancies. Cell Mol Immunol 3 (5): 359-365.
23. Burke JM, Jursic JG, Scheinberg DA, (2002) Radioimmunotherapy for acute leukemia. Cancer Control 9: 106-113.
24. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, et al. (2009) A robust xenotransplantation model for acute myeloid leukemia. Leukemia 23: 2109-2117.